|
Market Closed -
Nasdaq
04:00:00 2026-01-12 pm EST
|
5-day change
|
1st Jan Change
|
|
39.12 USD
|
+2.44%
|
 |
+6.04%
|
+249.49%
|
|
23-09-11 |
Adrenoleukodystrophy Clinical Trials, and Key Companies|Companies - Bluebird Bio, Minoryx Therapeutics, MedDay Pharmaceuticals, Magenta Therapeutics, Orpheris Inc, SOM Biotech, and many others
|
AQ
| |
23-09-11 |
Magenta Therapeutics, Inc.(NasdaqCM:MGTA) dropped from NASDAQ Composite Index
|
CI
| |
23-09-10 |
Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.
|
CI
| |
23-08-31 |
North American Morning Briefing : PCE Inflation -2-
|
DJ
| |
23-08-24 |
North American Morning Briefing : Nasdaq Futures -2-
|
DJ
| |
23-08-17 |
North American Morning Briefing : Treasury Yields Keep Pushing Higher
|
DJ
| |
23-08-10 |
North American Morning Briefing : Attention Turns -2-
|
DJ
| |
23-08-07 |
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
|
BU
| |
23-08-03 |
Magenta Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
|
CI
| |
23-06-23 |
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Index
|
CI
| |
23-06-23 |
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell Microcap Value Index
|
CI
| |
23-06-23 |
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Value Index
|
CI
| |
23-06-23 |
Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 3000E Index
|
CI
| |
23-05-19 |
Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer
|
CI
| |
23-05-15 |
Magenta Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
|
CI
| |
23-05-15 |
North American Morning Briefing : Hopes Build for -3-
|
DJ
| |
23-05-03 |
Shareholder Alert: Ademi LLP investigates whether Magenta Therapeutics, Inc. has obtained a Fair Price in its transaction with Dianthus
|
PR
| |
23-05-03 |
MAGENTA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Magenta Therapeutics, Inc. - MGTA
|
BU
| |
23-05-03 |
MGTA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Magenta Therapeutics, Inc. Is Fair to Shareholders
|
BU
| |
23-05-03 |
Dianthus Therapeutics, Inc., Magenta Therapeutics, Inc. - M&A Call
| | |
23-05-03 |
MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
|
AQ
| |
23-05-03 |
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
|
AQ
| |
23-05-02 |
Dianthus Therapeutics, Inc. entered into a definitive merger agreement to acquire Magenta Therapeutics, Inc. in a reverse merger transaction.
|
CI
| |
23-04-06 |
MAGENTA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement (form 8-K)
|
AQ
| |
23-04-06 |
Magenta Therapeutics, Inc. Enters into Sublease Termination and Release Agreement with Novartis Institutes for Biomedical Research, Inc
|
CI
|
No results for this search Select your edition All financial news and data tailored to specific country editions | 
